Ottimo Secures $140M Series A to Advance Jankistomig, a PD1/VEGFR2 Antibody, Towards Clinical Trials
Ottimo, a pioneering biotech company founded in collaboration with investment firm Medicxi and biotech leader Jonny Finlay, has emerged as a significant player in the field of novel cancer therapies. Under the strategic leadership of former Seagen CEO David Epstein, Ottimo secured over $140 million in Series A funding to advance its lead asset, jankistomig. Epstein's experienced management team includes notable figures such as former Boehringer Ingelheim chief medical officer Mehdi Shahidi and BioMarin's chief business officer James Sabry. This formidable leadership team is committed to leveraging their collective expertise to push forward Ottimo's mission of developing groundbreaking cancer treatments designed to extend patient lifespans[1][2].
References
- Former Seagen CEO's biotech raises $140M series A to ready PD1/VEGFR2 antibody for clinic
- <a href="https://www.fiercebiotech.com/biotech/former-seagen-ceos-biotech-raises-140m-series-ready-pd1vegfr2-antibody-clinic" hreflang="en">Former Seagen CEO's biotech raises $140M series A to ready PD1/VEGFR2 antibody for clinic</a>
Explore Further
How does Ottimo plan to differentiate jankistomig from existing cancer therapies like Keytruda in terms of efficacy and safety?
What are the specific milestones Ottimo aims to achieve after filing the Investigational New Drug (IND) application for jankistomig in 2025?
How does the dual-targeting mechanism of jankistomig impact its potential effectiveness in treating different types of cancer?
What are the anticipated challenges Ottimo might face as it progresses jankistomig from preclinical to clinical trials?
How does the leadership experience of former Seagen CEO David Epstein and his team contribute to Ottimo's strategy for jankistomig's development and market entry?